Institution Directory

Clinical trials at Mount Sinai

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1101

Shown on this page

Current sort

Live official records

Conditions: Sexually Transmitted Diseases, Sexual Health, Reproductive Health
Interventions: Health-E You app; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 13 Years to 21 Years · Male only
Enrollment: 2,752 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Oakland, California • Washington D.C., District of Columbia • Baltimore, Maryland + 5 more

Conditions: Non-small Cell Lung Cancer
Interventions: fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 29
States / cities: Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more

Conditions: Pulmonary Embolism
Interventions: The Bashir™ Endovascular Catheter, r-tPA; Device · Drug
Lead sponsor: Thrombolex, Inc.; Industry
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Scottsdale, Arizona • Tuscon, Arizona • Lakeland, Florida + 19 more

Conditions: Ovarian Cancer
Interventions: Gleolan; Drug
Lead sponsor: NX Development Corp; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 11
States / cities: Phoenix, Arizona • Jacksonville, Florida • Annapolis, Maryland + 8 more

Conditions: Non-small Cell Lung Cancer
Interventions: SBRT, First or second-line standard of care therapy; Radiation · Other
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 71
States / cities: Phoenix, Arizona • Duarte, California • Irvine, California + 55 more

Conditions: Multiple Myeloma
Interventions: Etentamig (ABBV-383); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 27
States / cities: Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 23 more

Conditions: Central Nervous System Carcinoma
Interventions: Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 4 Years to 17 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 137
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more

Conditions: FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
Interventions: TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin; Combination Product
Lead sponsor: TORL Biotherapeutics, LLC; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Fullerton, California • Irvine, California • Los Angeles, California + 3 more

Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Interventions: Cyclophosphamide, Vincristine, Dexamethasone, Inotuzumab Ozogamicin, Methotrexate, Cytarabine, Methylprednisolone, Rituximab, Prednisone, Mercaptopurine, Doxorubicin; Drug · Biological
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 50 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 71
States / cities: Birmingham, Alabama • Irvine, California • Orange, California + 60 more

Conditions: Central Centrifugal Cicatricial Alopecia, Frontal Fibrosing Alopecia
Interventions: Deucravacitinib; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions: AAA617, 68Ga-PSMA-11; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Fluorouracil, Gemcitabine, Gemcitabine Hydrochloride, Leucovorin, Leucovorin Calcium, Liposomal Irinotecan, Nab-paclitaxel, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 70 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 760
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 501 more

About this Mount Sinai institution page

What this page lists: ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mount Sinai

Filter and sort this campus

Live official records

Health-E You Efficacy Trial for Male Adolescents

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia

Deucravacitinib in the Treatment of Cicatricial Alopecias

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

About this Mount Sinai institution page